title: Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
abstract: The aim of the study was to compare the effects on bone mass and turnover of continuous vs. intermittent clodronate administration on 120 postmenopausal women (average age 61 years) with low bone mass (femoral neck bone mineral density [BMD] of at least -1 SD or more, T-score), with another 30 women as a control group. Participants were given 1800 mg of clodronate every 6 months over 2 years using different treatment patterns: a) two continuous regimens, consisting of a daily oral dose of 400 mg or 100 mg every 10 days by intramuscular injection, the latter being considered continuous because the interval between injections is shorter than the time employed by each bone remodelling unit to complete the resorption phase of a remodelling cycle; and b) two intermittent regimens, consisting of 1800 mg every 6 months administered either as a single 18-h intravenous infusion or by separate infusions of 300 mg over 6 consecutive days. All women, including those in the control group, received calcium and vitamin D supplementation. After 2 years, continuous clodronate regimens caused an increase in BMD both at lumbar spine and proximal femur (L(1-4) BMD = 3.07% and 2.69%; femoral neck = 2.12% and 2.09%, respectively, with intramuscular and oral regimens). Intermittent clodronate administration was associated with a small increase or a stabilization in bone mass (L(1-4) BMD = 0.53% and 1.22%; femoral neck = 0.30% and 0.77%, respectively, with 1- and 6-day intravenous infusion regimens). From the 12th month, changes in spine and femoral neck BMD after continuous regimens were statistically different compared with that obtained with intermittent ones. Twenty-five of the 150 women (16.7%) discontinued the study before the end of the 2-year follow-up, but of these, only 7 dropped out because of adverse events related to the treatment itself. To summarize, intermittent clodronate administration could be a suitable option for the prevention of osteoporosis.
authors.affiliation: Bone and Mineral Research Unit, University of Perugia, Italy. bonemres@tin.it
authors.forename: P
authors.initials: P
authors.lastname: Filipponi
authors.forename: S
authors.initials: S
authors.lastname: Cristallini
authors.forename: G
authors.initials: G
authors.lastname: Policani
authors.forename: M F
authors.initials: MF
authors.lastname: Schifini
authors.forename: C
authors.initials: C
authors.lastname: Casciari
authors.forename: P
authors.initials: P
authors.lastname: Garinei
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects*; D004002:Clodronic Acid / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000378:metabolism / Q000517:prevention & control; D017698:Postmenopause
chemical_list: D015415:Biomarkers; D004002:Clodronic Acid